Published 30-Day FRN

90832

Federal Register / Vol. 89, No. 222 / Monday, November 18, 2024 / Notices

POLICIES AND PRACTICES FOR STORAGE OF
RECORDS:

Pre-existing paper and microfiche
records were digitized. Input records are
maintained digitally on electronic
storage media in accordance with the
safeguards below.
POLICIES AND PRACTICES FOR RETRIEVAL OF
RECORDS:

RECORD ACCESS PROCEDURES:

Records can be retrieved by name,
SSN, employee IDs, organizational code,
home address, or a combination of the
information listed in the categories of
records.
POLICIES AND PRACTICES FOR RETENTION AND
DISPOSAL OF RECORDS:

Records in the system are maintained
in accordance with the following
NARA’s records retention and
schedules: General Records Schedule
(GRS) 2.3, Employee Relations Records,
Item 10, Employee relations programs’
administrative records, DAA–GRS–
2018–0002–0001, Temporary. Destroy
when 3 years old, but longer retention
is authorized if required for business
use; Item 40, Telework/alternate
worksite program, DAA GRS–2018–
0002–0004, Temporary. Destroy when 3
years old, but longer retention is
authorized if required for business use.
GRS 2.4, Employee Compensation and
Benefits Records, Item 10, Records used
to calculate payroll, arrange paycheck
deposit, and change previously issued
paychecks, DAA–2018–0002–0001:
Temporary. Destroy when 3 years old,
but longer retention is authorized if
required for business use. Item 30, Time
and attendance records, DAAGRS–
2019–0004–0002, Temporary, destroy
when 3 years old, but longer retention
is authorized if required for business
use. Item 40, Agency payroll record for
each pay period, DAA–GRS–2016–
00015–0004, Destroy when 56 years old.
GRS 4.2, Information Access, and
Protection Records, Item 130, Personally
identifiable information extracts, DAA–
GRS–2013–0007–0012, Temporary.
Destroy when 90 days old or no longer
needed pursuant to supervisory
authorization, whichever is appropriate.

lotter on DSK11XQN23PROD with NOTICES1

ADMINISTRATIVE, TECHNICAL, AND PHYSICAL
SAFEGUARDS:

Administrative Procedures: Access to
the records is limited to person(s)
responsible for servicing the records in
performance of their official duties, who
are properly screened, trained on
policies and procedures, and cleared for
need to-know. Personnel who access the
system and its data must take security
awareness training and sign a Rules of
Behavior initially (prior to access) and,
at least, annually thereafter. Technical:
Regular monitoring of users and the

VerDate Sep<11>2014

17:17 Nov 15, 2024

Jkt 265001

system are implemented to ensure only
authorized personnel have access to
information in the system. Strict
controls are in place to minimize the
compromise of stored or accessed in the
system. Physical: The system and the
data are housed in secure data center.

Individuals seeking access to records
about themselves contained in this
system should address inquiries to the
System Manager at the address
identified in ‘‘System Manager and
Address’’ above. Request must be in
writing, include SORN ID and name of
this system of records notice,
information on the Operating
Administration-Department, specific
date range and specific type of records
seeking. Request must be signed by the
requester, must be notarized as required
by 28 U.S.C. 1746 in the following
format: If executed without the United
States: ‘‘I declare (or certify, verify, or
state) under penalty of perjury under the
laws of the United States of America
that the foregoing is true and correct.
Executed on (date). (Signature)’’. If
executed within the United States, its
territories, possessions, or
commonwealths: ‘‘I declare (or certify,
verify, or state) under penalty of perjury
that the foregoing is true and correct.
Executed on (date). (Signature)’’.
CONTESTING RECORD PROCEDURES:

See ‘‘Records Access Procedures’’
above.
NOTIFICATION PROCEDURES:

See ‘‘Records Access Procedures’’
above.
EXEMPTIONS PROMULGATED FOR THE SYSTEM:

None.
HISTORY:

A full notice of this system of records,
DOT/ALL 11, Integrated Personnel
Payroll System, was published in the
Federal Register on November 7, 2008
(73 FR 66285), April 11, 2000 (65 FR
19845).
Issued in Washington, DC.
Karyn Gorman,
Chief Privacy Officer.
[FR Doc. 2024–26743 Filed 11–15–24; 8:45 am]
BILLING CODE 4910–9X–P

PO 00000

Frm 00170

Fmt 4703

Sfmt 4703

DEPARTMENT OF VETERANS
AFFAIRS
[OMB Control No. 2900–0890]

Agency Information Collection Activity
Under OMB Review: Industry Standard
Forms for Completing an Appraisal
Required by VA
Veterans Benefits
Administration, Department of Veterans
Affairs.
ACTION: Notice.
AGENCY:

In compliance with the
Paperwork Reduction Act (PRA) of
1995, this notice announces that the
Veterans Benefits Administration,
Department of Veterans Affairs, will
submit the collection of information
abstracted below to the Office of
Management and Budget (OMB) for
review and comment. The PRA
submission describes the nature of the
information collection and its expected
cost and burden and it includes the
actual data collection instrument.
DATES: Comments and
recommendations for the proposed
information collection should be sent by
December 18, 2024.
ADDRESSES: To submit comments and
recommendations for the proposed
information collection, please type the
following link into your browser:
www.reginfo.gov/public/do/PRAMain,
select ‘‘Currently under Review—Open
for Public Comments’’, then search the
list for the information collection by
Title or ‘‘OMB Control No. 2900–0890.’’
SUPPLEMENTARY INFORMATION:
Title: Industry Standard Forms for
Completing an Appraisal Required by
VA FNMA Forms 1004, 1004C, 1004D,
1004 (Desktop), 1025, 1073, 1075 and
2055
OMB Control Number: 2900–0890.
Type of Review: Extension without
change of a currently approved
collection.
Abstract: This information collection
package seeks approval of VA’s
requirement that appraisers utilize
certain industry-standard forms in
completing an appraisal. 38 U.S.C. 3731
authorizes the VA Secretary to establish
a panel of appraisers, prescribe
qualifications for such appraisers, and
determine reasonable value of a
property, construction, repairs or
alterations based on an appraisal report
provided by a panel appraiser for the
purpose of guaranteeing a loan.
VA is requesting approval to
authorize collection of these forms
because accurate and thorough appraisal
reporting is critical to the accuracy of
underwriting for the mortgage process.
SUMMARY:

E:\FR\FM\18NON1.SGM

18NON1

Federal Register / Vol. 89, No. 222 / Monday, November 18, 2024 / Notices
Additionally, VA is looking to expand
the list of authorized forms for use due
to ongoing needs related to the
pandemic. This collection of
information provides a more thorough
and complete appraisal of prospective
VA-guaranteed properties ensuring that
mortgages are acceptable for VA
guarantee and thereby protect the
interest of VA, taxpayers, and the
Veterans Housing Benefit Program
Fund. Policies and procedures for
governing the VA appraisal program are
set forth in Chapter 36, Title 38 of the
CFR.
An agency may not conduct or
sponsor, and a person is not required to
respond to a collection of information
unless it displays a currently valid OMB
control number.
The Federal Register Notice with a
60-day comment period soliciting
comments on this collection of
information was published at 89 FR
73508, September 10, 2024.
Affected Public: Individuals or
Households.
Estimated Annual Burden: 10,833.
Estimated Average Burden per
Respondent: 1 minute.
Frequency of Response: One time.
Estimated Number of Respondents:
650,000.
(Authority: 44 U.S.C. 3501 et seq.)
Maribel Aponte,
VA PRA Clearance Officer, Office of
Enterprise and Integration, Data Governance
Analytics, Department of Veterans Affairs.
[FR Doc. 2024–26803 Filed 11–15–24; 8:45 am]
BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS
AFFAIRS
Findings of Research MisconductC
Department of Veterans Affairs.
Notice.

AGENCY:
ACTION:

The Department of Veterans
Affairs (VA), gives notice, pursuant to
Veterans Health Administration (VHA)
Directive 1058.02 ‘‘Research
Misconduct’’ section 8.l, that the
Department has made findings of
research misconduct against Alan
Lichtenstein, M.D. (‘‘Respondent’’), a
former staff physician at the VA Greater
Los Angeles Healthcare System, Los
Angeles, CA. The Respondent did not
appeal the findings or corrective actions
against him.
FOR FURTHER INFORMATION CONTACT:
Shara Kabak, Research Misconduct
Officer, Office of Research Oversight
(10RO), 810 Vermont Avenue NW,
Washington, DC 20420, (202) 632–7620
(this is not a toll-free number).

lotter on DSK11XQN23PROD with NOTICES1

SUMMARY:

VerDate Sep<11>2014

17:17 Nov 15, 2024

Jkt 265001

VA has
made final findings of research
misconduct against Alan Lichtenstein,
M.D. (‘‘Respondent’’), a former staff
physician at the VA Greater Los Angeles
Healthcare System in Los Angeles, CA.
Based on the recommended findings
of a joint investigation conducted by VA
Greater Los Angeles Healthcare System
and University of California, Los
Angeles School of Medicine, the
Department found that the Respondent
engaged in research misconduct by
recklessly falsifying data included in at
least ten of the following thirteen
published papers:
• DEPTOR is linked to a TORC1-p21
survival proliferation pathway in
multiple myeloma. Genes & Cancer.
2014 Nov;5(11–12):407–19. doi:
10.18632/genesandcancer.44 (hereafter,
‘‘Genes Cancer 2014’’).
• Cytotoxic properties of a DEPTORmTOR inhibitor in multiple myeloma
cells. Cancer Research. 2016 Oct
1;76(19):5822–5831. doi: 10.1158/0008–
5472. CAN–16–1019 (hereafter, ‘‘Cancer
Res. 2016’’).
• Interleukin-6 activates
phosphoinositol-3 kinase in multiple
myeloma tumor cells by signaling
through RAS-dependent and, separately,
through p85-dependent pathways.
Oncogene. 2004 Apr 22;23(19):3368–75.
doi: 10.1038/sj.onc.1207459 (hereafter,
‘‘Oncogene 2004’’).
• MNK1-induced eIF–4E
phosphorylation in myeloma cells: a
pathway mediating IL–6-induced
expansion and expression of genes
involved in metabolic and proteotoxic
responses. PLoS One. 2014 Apr
8;9(4):e94011. doi: 10.1371/
journal.pone.0094011 (hereafter, ‘‘PLoS
One 2014’’). Retraction in: PLoS One.
2023 Sep 8;18(9):e0291491. doi:
10.1371/journal.pone.0291491.
• Mammalian target of rapamycin
inhibitors activate the AKT kinase in
multiple myeloma cells by up-regulating
the insulin-like growth factor receptor/
insulin receptor substrate-1/
phosphatidylinositol 3-kinase cascade.
Molecular Cancer Therapeutics. 2005
Oct;4(10):1533–40. doi: 10.1158/1535–
7163.MCT–05–0068 (hereafter, ‘‘Mol
Cancer Ther. 2005’’).
• Inhibition of SAPK2/p38 enhances
sensitivity to mTORC1 inhibition by
blocking IRES-mediated translation
initiation in glioblastoma. Molecular
Cancer Therapeutics. 2011 10:2244–
2256 Dec;10(12):2244–56. doi: 10.1158/
1535–7163.MCT–11–0478 (hereafter,
‘‘Mol Cancer Ther. 2011’’).
• Specific blockade of Rictor-mTOR
association inhibits mTORC2 activity
and is cytotoxic in glioblastoma. PLoS
One. 2017; Apr 28;12(4):e0176599. doi:

SUPPLEMENTARY INFORMATION:

PO 00000

Frm 00171

Fmt 4703

Sfmt 4703

90833

10.1371/journal.pone.0176599
(hereafter, ‘‘PLoS One 2017’’).
Correction in: PLoS One. 2019 Feb
6;14(2):e0212160. doi: 10.1371/
journal.pone.0212160. Retraction in:
PLoS One. 2023 Sep 8;18(9):e0291490.
doi: 10.1371/journal.pone.0291490.
• MNK kinases facilitate c-myc IRES
activity in rapamycin-treated multiple
myeloma. Oncogene. 2013 Jan
10;32(2):190–7. doi: 10.1038/
onc.2012.43 (hereafter, ‘‘Oncogene
2013’’). Expression of Concern in:
Oncogene. 2023 Oct;42(41):3088. doi:
10.1038/s41388–023–02818–z.
• The PP242 mammalian target of
rapamycin (mTOR) inhibitor activates
extracellular signal-regulated kinase
(ERK) in multiple myeloma cells via a
target of rapamycin complex 1 (TORC1)/
eukaryotic translation initiation factor
4E (eIF–4E)/RAF pathway and
activation is a mechanism of resistance.
Journal of Biological Chemistry. 2012
Jun 22;287(26):21796–805. doi: 10.1074/
jbc.M111.304626 (hereafter, ‘‘J Biol
Chem. 2012’’).
• Therapeutic potential of targeting
IRES-dependent c-myc translation in
multiple myeloma cells during ER
stress. Oncogene. 2016 Feb
25;35(8):1015–24. doi: 10.1038/
onc.2015.156 (hereafter, ‘‘Oncogene
2016’’). Retraction in: Oncogene. 2023
Sep;42(40):3016. doi: 10.1038/s41388–
023–02820–5.
• SGK kinase activity in multiple
myeloma cells protects against ER stress
apoptosis via a SEK-dependent
mechanism. Molecular Cancer
Research. 2016 Apr;14(4):397–407. doi:
10.1158/1541–7786.MCR–15–0422
(hereafter, ‘‘Mol Cancer Res. 2016’’).
• A novel therapeutic induces
DEPTOR degradation in multiple
myeloma cells with resulting tumor
cytotoxicity. Molecular Cancer
Therapeutics. 2019 Oct;18(10):1822–
1831. doi: 10.1158/1535–7163.MCT–19–
0115 (hereafter, ‘‘Mol Cancer Ther.
2019’’).
• Downstream effectors of oncogenic
ras in multiple myeloma cells. Blood.
2003 Apr 15;101(8):3126–35. doi:
10.1182/blood–2002–08–2640
(hereafter, ‘‘Blood 2003’’).
Specifically, the Department found
that the Respondent recklessly
committed research misconduct by
reusing the same Western blot or kinase
assay image to falsely represent the
results related to the following pairs of
experiments such that at least one of the
sets of images in each of the pairs listed
below is inaccurate:
• p-4E–BP1–T37/46, p–4E–BP1–S65
and Tubulin expression in Figure 3B of
Genes Cancer 2014 and Figure 1F of
Cancer Res. 2016.

E:\FR\FM\18NON1.SGM

18NON1